Travere Therapeutics Reports Record FILSPARI Sales and Prepares for FSGS Approval Decision
核心洞察
Travere Therapeutics achieved record quarterly performance with FILSPARI generating approximately $103 million in net sales and 908 new patient starts in Q4 2025.
The company awaits FDA approval decision for FILSPARI in FSGS by January 13, 2026, which would mark the first approved medication for this rare kidney disorder.
Travere plans to restart its pivotal Phase 3 HARMONY study of pegtibatinase for classical homocystinuria (搜索) in Q1 2026 following manufacturing optimization.
Travere Therapeutics delivered exceptional commercial performance in the fourth quarter of 2025, with its kidney disease therapy FILSPARI (sparsentan) achieving record-breaking sales and patient enrollment metrics. The company reported preliminary net product sales of approximately $103 million for FILSPARI in Q4 2025, representing 108% year-over-year growth, while receiving 908 new patient start forms during the quarter.
The strong commercial execution contributed to total U.S. net product sales of approximately $127 million for the fourth quarter and $410 million for the full year 2025. Travere ended 2025 with approximately $323 million in cash, cash equivalents, and marketable securities, positioning the company for continued operations and pipeline advancement.
"The fourth quarter closed out an exceptional year of commercial execution with FILSPARI, as our teams were able to reach a record number of patients with IgAN, reinforcing its role as foundational therapy," said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics.
Pending FSGS Approval Decision
Travere faces a critical regulatory milestone with the FDA's PDUFA target action date of January 13, 2026, for FILSPARI's supplemental New Drug Application in focal segmental glomerulosclerosis (搜索) (FSGS). The company recently received additional information requests from the FDA to further characterize the clinical benefit of FILSPARI and has submitted responses that are currently under agency review.
If approved, FILSPARI would become the first and only medication approved for FSGS, a rare kidney disorder that represents a leading cause of kidney failure (搜索). The potential approval would significantly expand the addressable patient population for FILSPARI beyond its current indication in IgA nephropathy (搜索) (IgAN).
"As we move into 2026, we are focused on sustaining this momentum while preparing for a successful commercial launch of FILSPARI in FSGS, which, if approved, would be the first approved medication for these patients facing potential kidney failure (搜索)," Dube stated.
Pipeline Development Progress
The company announced plans to restart its pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (搜索) (HCU) in the first quarter of 2026. This restart follows optimization of the manufacturing process throughout 2025, addressing previous production challenges that had delayed the study.
Pegtibatinase represents a potential first-in-class, disease-modifying therapy for patients with classical HCU, a rare genetic disorder affecting amino acid metabolism. The HARMONY study restart marks a significant milestone in advancing this treatment option for an underserved patient population.
International Expansion and Partnerships
Travere's international partnerships continue to generate value, with the company receiving a $40 million milestone payment from collaborator CSL Vifor (搜索) in October 2025 following market access achievements. CSL Vifor has successfully launched FILSPARI in Germany, Austria, Switzerland, Luxembourg, and the UK, with Travere remaining eligible for additional market access and sales-based milestones.
The company's partnership with Chugai Pharmaceutical is expected to yield further regulatory progress in 2026, with the Japanese partner planning to submit a New Drug Application for sparsentan in Japan. This submission would potentially expand FILSPARI's global reach while generating additional milestone payments and tiered royalties for Travere.
Safety Profile and Clinical Considerations
FILSPARI carries a boxed warning for hepatotoxicity and embryo-fetal toxicity, requiring enrollment in a restricted distribution program called FILSPARI REMS. Clinical studies have observed elevations in aminotransferases of at least three times the upper limit of normal in up to 3.5% of FILSPARI-treated patients.
The most common adverse reactions include hyperkalemia, hypotension, peripheral edema, dizziness, anemia, and acute kidney injury. The drug is contraindicated in pregnant patients and requires careful monitoring of liver function, blood pressure, and kidney function during treatment.
FILSPARI is currently indicated to slow kidney function decline in adults with primary IgA nephropathy (搜索) who are at risk for disease progression, representing a significant advancement in treating this progressive kidney disease that can lead to end-stage renal disease requiring dialysis or transplantation.